MX2022005029A - Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2. - Google Patents

Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2.

Info

Publication number
MX2022005029A
MX2022005029A MX2022005029A MX2022005029A MX2022005029A MX 2022005029 A MX2022005029 A MX 2022005029A MX 2022005029 A MX2022005029 A MX 2022005029A MX 2022005029 A MX2022005029 A MX 2022005029A MX 2022005029 A MX2022005029 A MX 2022005029A
Authority
MX
Mexico
Prior art keywords
inhibitor
mace
methods
combination
prevention
Prior art date
Application number
MX2022005029A
Other languages
English (en)
Inventor
Kenneth Eugene Lebioda
Christopher Ross Armstrong Halliday
Aziz Naeem Khan
Original Assignee
Resverlogix Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resverlogix Corp filed Critical Resverlogix Corp
Publication of MX2022005029A publication Critical patent/MX2022005029A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

En este documento se describen métodos para tratar y/o prevenir acontecimientos cardiovasculares adversos graves (MACE) al administrar a un sujeto necesitado de los mismos, una combinación de un inhibidor de la proteína de transporte de sodio-glucosa 2 (SGLT2) y un compuesto de la Fórmula I o un estereoisómero, tautómero, sal farmacéuticamente aceptable o hidrato del mismo, en donde las variables de la Fórmula I son como se define en este documento. (ver Fórmula).
MX2022005029A 2019-11-05 2020-11-04 Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2. MX2022005029A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962930860P 2019-11-05 2019-11-05
PCT/IB2020/000912 WO2021090061A1 (en) 2019-11-05 2020-11-04 Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Publications (1)

Publication Number Publication Date
MX2022005029A true MX2022005029A (es) 2022-07-12

Family

ID=75849803

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005029A MX2022005029A (es) 2019-11-05 2020-11-04 Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2.

Country Status (12)

Country Link
US (1) US20220370452A1 (es)
EP (1) EP4054584A4 (es)
JP (1) JP2023500685A (es)
KR (1) KR20220098757A (es)
CN (1) CN114650824A (es)
AU (1) AU2020377539A1 (es)
BR (1) BR112022008223A2 (es)
CA (1) CA3160147A1 (es)
IL (1) IL292696A (es)
MX (1) MX2022005029A (es)
TW (1) TW202131924A (es)
WO (1) WO2021090061A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015025228A2 (en) * 2013-08-21 2015-02-26 Resverlogix Corp. Compositions and therapeutic methods for accelerated plaque regression
BR112016003584A8 (pt) * 2013-08-21 2018-01-30 Resverlogix Corp composições farmaceuticas e uso das mesmas para regressão de placa acelerada
WO2016147053A1 (en) * 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US20230398137A1 (en) * 2020-10-30 2023-12-14 Resverlogix Corp. Methods for lowering hba1c level with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor

Also Published As

Publication number Publication date
TW202131924A (zh) 2021-09-01
IL292696A (en) 2022-07-01
EP4054584A4 (en) 2023-11-08
CN114650824A (zh) 2022-06-21
AU2020377539A1 (en) 2022-05-19
CA3160147A1 (en) 2021-05-14
KR20220098757A (ko) 2022-07-12
US20220370452A1 (en) 2022-11-24
WO2021090061A1 (en) 2021-05-14
JP2023500685A (ja) 2023-01-10
BR112022008223A2 (pt) 2022-09-06
EP4054584A1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
EP4331677A3 (en) Methods of treating feline coronavirus infections
MX2022006663A (es) Compuesto heterociclico que contiene oxigeno, metodo de preparacion de este y uso de este.
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
PH12020550107A1 (en) Chromane monobactam compounds for the treatment of bacterial infections
MX365138B (es) Inhibidores de prolil hidroxilasa.
TW200639159A (en) Treatment of pain
EA200970933A1 (ru) Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста
PH12019500177A1 (en) Treatment and prevention of sleep disorders
WO2020033838A3 (en) Treatment of egfr-mutant cancer
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
CR20230052A (es) Combinaciones para el tratamiento de cáncer.
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2020010697A (es) Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil.
MX2021012105A (es) Compuestos de pirrol.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
SG11201907945YA (en) Azetidine derivative
MX2022011490A (es) Tratamiento o metodo de prevencion de falla cardiaca cronica.
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2022005029A (es) Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2.
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
MX2021012824A (es) Métodos para tratar el prurito.